Category: 70631-93-5

70631-93-5, name is 5-Methyl-1H-imidazole-2-carboxylic acid, belongs to imidazoles-derivatives compound, is considered to be a conventional heterocyclic compound, which is widely used in drug synthesis. The chemical synthesis route is as follows. name: 5-Methyl-1H-imidazole-2-carboxylic acid

A mixture of N-cyclopropyl-8-((4-methoxybenzyl)(methyl)amino)-6-((2-oxo- 1- (piperidin-4-yl)- 1 ,2-dihydropyridin-3 -yl)amino)imidazo[ 1 ,2-b]pyridazine-3-carboxamide(0.0 15 g, 0.028 mmol), 4-methyl-1H-imidazole-2-carboxylic acid (6.97 mg, 0.055 mmol), BOP (0.024 g, 0.055 mmol) and N,N-Di-iso-propylethylamine (0.018 g, 0.138 mmol) in DMF (1.0 mL) was stirred at room temperature overnight. The reaction mixture was concentrated. The residue was dissolved in 2m1 dichloromethane. 0.2 ml TFA was added and the reaction mixture stirred at room temperature overnight. The crude productmixture was chromatographed using Reverse-Phase PREP LC to give N-cyclopropyl-6- ((1 -(1 -(4-methyl- 1H-imidazole-2-carbonyl)piperidin-4-yl)-2-oxo- 1 ,2-dihydropyridin-3- yl)amino)-8-(methylamino)imidazo [1 ,2-b]pyridazine-3 -carboxamide (0.007g, 0.014 mmol, 50% yield) as a white solid.

The synthetic route of 70631-93-5 has been constantly updated, and we look forward to future research findings.

Reference:
Patent; BRISTOL-MYERS SQUIBB COMPANY; LIU, Chunjian; LIN, James; MOSLIN, Ryan M.; WEINSTEIN, David S.; TOKARSKI, John S.; WO2015/89143; (2015); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

In the chemical reaction process, reaction time, type of solvent, can easily affect the result of the reaction, thereby determining the yield and properties of the reaction product. An updated downstream synthesis route of 70631-93-5 as follows. Product Details of 70631-93-5

To a stirred solution of 4-methyMH-imidazole-2-carboxylic acid (0.50 g) in DMF (20 mL) were added N,Odimethyl hydroxylamine hydrochloride (0.43 g), TEA (1.7 mL) and HATU (1.8 g). The mixture was stirred for 4 hours at 80C and stirred at room temperature for 2 days. The reaction mixture was concentrated in vacuo and the precipitates were filtered out. The filtrate was concentrated in vacuo and the residue was purified with amino-type silica gel chromatography (0″5 % MeOH in CHCI3) to give the title compound (0.41 g, 61 % yield) as pale yellow oil. MS (ESI) m/z : 170 [M+l]. RT = 0.206 min. LCMS condition : A.

According to the analysis of related databases, 70631-93-5, the application of this compound in the production field has become more and more popular.

Reference:
Patent; TAISHO PHARMACEUTICAL CO., LTD.; TAKASHIMA, Hajime; SASAKI, Toru; TANAKA, Nozomi; OTAKE, Norikazu; TSURUTA, Risa; YAMADA, Yousuke; MATSUDA, Yohei; OGATA, Yuya; (346 pag.)WO2018/216822; (2018); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

70631-93-5, name is 5-Methyl-1H-imidazole-2-carboxylic acid, belongs to imidazoles-derivatives compound, is considered to be a conventional heterocyclic compound, which is widely used in drug synthesis. The chemical synthesis route is as follows. Safety of 5-Methyl-1H-imidazole-2-carboxylic acid

Example 527 2-(((3R,4S)-3-fluoro-1-(4-methyl-1H-imidazole-2-carbonyl)piperidin-4-yl)oxy)-5-(4-((4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)amino)-1,3,5-triazin-2-yl)benzonitrile 3-Fluoro-2-(((3R,4S)-3-fluoropiperidin-4-yl)oxy)-5-(4-((4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)amino)-1,3,5-triazin-2-yl)benzonitrile (82 mg, 0.15 mmol), HATU (117 mg, 0.31 mmol), TEA (76 mg, 0.62 mmol) and 4-methyl-1H-imidazole-2-carboxylic acid (41 mg, 0.31 mmol) were dissolved in DMF (4 mL) and stirred at room temperature overnight. The mixture was concentrated and the residue was purified by silica gel column with 5-20% MeOH in CH2Cl2 to give the product. 1H NMR (400 MHz, DMSO-d6) delta 12.63 (m, 1H), 10.12 (d, 1H), 8.83-8.34 (m, 2H), 7.83-7.33 (m, 4H), 6.76 (d, 1H), 5.91-5.55 (m, 1H), 5.37 (s, 1H), 5.08 (m, 3H), 4.51 (m, 4H), 4.30 (d, 1H), 3.79 (m, 1H), 3.43 (m, 1H), 3.13 (s, 4H), 2.40 (t, 4H), 2.15 (s, 3H), 1.65-1.98 (m, 2H).

The synthetic route of 70631-93-5 has been constantly updated, and we look forward to future research findings.